Clinical Trials Logo

Gonadal Dysgenesis clinical trials

View clinical trials related to Gonadal Dysgenesis.

Filter by:

NCT ID: NCT00699855 Completed - Clinical trials for Turner Syndrome in Pre-pubertal Children

Long Term Follow up Study of Predictive Markers in GHD and TS Children

PREDICT LT FUP
Start date: September 2008
Phase: N/A
Study type: Observational

Primary objective is to assess the relationship between changes from serum biomarkers observed after 1 month of Saizen® therapy and change in height, weight after up to 5 years of treatment with Growth Hormone in children with Growth Hormone Deficiency (GHD) and Turner Syndrome (TS).

NCT ID: NCT00650754 Terminated - Clinical trials for Primary Ovarian Insufficiency

Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

DHEAFert
Start date: March 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The experimental focus of this project is on the interaction of DHEA treatment on pregnancy in women with otherwise unexplained infertility and evidence of premature ovarian aging (POA).

NCT ID: NCT00625001 Active, not recruiting - Turner Syndrome Clinical Trials

Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome

Start date: November 1994
Phase: N/A
Study type: Observational

Turner Syndrome (TS) is associated with osteopenia and osteoporosis. Reduced bone mineral density (BMD) and increased risk of fractures are present in many younger and middle-aged women with TS. The objective is therefore to describe longitudinal changes in BMD in TS. The study is an observational follow-up study. Examinations at baseline, after 5 and 10 years. Bone mineral density is measured by dual energy x-ray absorptiometry (DEXA) and bone turnover by bone markers. Main Outcome Measures: Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm.

NCT ID: NCT00624949 Active, not recruiting - Turner Syndrome Clinical Trials

Aortic Dimensions in Turner Syndrome

Start date: August 2003
Phase: N/A
Study type: Observational

An observational study of 102 women with Turner syndrome followed for 6 years with a two-yearly examination including ECHO, MRI of the heart and 24 ambulatory blood pressure. It has been found that besides an significantly increased risk of congenital cardiac malformations, TS have an increased risk of developing cardiac disease including the life threatening condition of aortic dilatation and rupture. The aim of the study is to describe the cardiac conditions of TS, evaluate different methods of examination and identify possible risc factors.

NCT ID: NCT00594763 Active, not recruiting - Clinical trials for Thromboembolic Disease

Venous Thrombosis in Turner Syndrome

Start date: June 2006
Phase: N/A
Study type: Observational

In the literature, cases of thrombosis in the venous system have been described in girls and women with Turner syndrome. By screening a group of women with Turner syndrome, the researchers wish to find out if this condition is more frequent in this patient population.

NCT ID: NCT00471731 Completed - Menopause Clinical Trials

Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure

Start date: May 7, 2007
Phase: N/A
Study type: Observational

Premature ovarian failure (POF) is known to be associated with an increased risk of ocular surface disease (dry eye), likely due to the reduction of both estrogens and androgens seen in this condition. From preliminary data, we suspect that women with Turners syndrome (45, XO), a genetic abnormality that affects sex hormone levels, are also at increased risk of ocular surface disease. Comparing POF and TS women may allow us to distinguish different mechanisms for ocular surface disease, due to the different etiologies of hormonal (estrogen and androgen) alterations posed by POF and TS.

NCT ID: NCT00443144 Completed - Turner Syndrome Clinical Trials

D3-GHR Polymorphism and Turner Syndrome

Start date: May 2005
Phase: N/A
Study type: Observational

The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome. Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).

NCT ID: NCT00420654 Completed - Turner Syndrome Clinical Trials

Growth Hormone Treatment of Women With Turner Syndrome

Start date: August 2007
Phase: N/A
Study type: Interventional

Growth hormone treatment is used in girls with Turner syndrome to increase final height. The aim of this study is to evaluate the effect of growth hormone treatment on body composition and heart function in adult women with Turner syndrome. The hypothesis is that the fat mass will decrease and lean body mass will increase. There is only very limited documentation of the effect on the heart in this study population.

NCT ID: NCT00419107 Terminated - Turner Syndrome Clinical Trials

Beta Cell Function in Women With Turner Syndrome

Start date: November 2004
Phase: N/A
Study type: Observational

Diabetes is more frequent in women with Turner syndrome. The purpose of this study is to see, in what ways the glucose metabolism is different in this study population. The hypothesis is that women with Turner Syndrome have an impaired insulin production (beta cell function).

NCT ID: NCT00406926 Completed - Turner Syndrome Clinical Trials

The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

Start date: August 1999
Phase: Phase 3
Study type: Interventional

This study investigated the effect of growth hormone on the growth of infants and toddlers with Turner syndrome during 2 years of treatment with growth hormone. This was compared with the growth of infants and toddlers with Turner syndrome who did not receive any growth hormone treatment. The overall aim was to prevent the growth failure usually seen during this period. The study also looked at middle ear disease, hearing problems, and cognitive and behavioral development.